NG
NervGen Pharma Corp.
NGENF · OTC
$3.95 -2.47% (-$0.10)
Market Cap $429.5M
P/E Ratio -
Div. Yield -
ROE 97,459.80%
Bulios Fair Price
$2.23
43.5% downside
Current Price
$3.95
Undervalued Fair Value Overvalued
According to Bulios Fair Price, NGENF is currently overvalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Piotroski F-Score Weak
1/9Valuation
-
N/A P/E N/A
EV/EBITDA N/A
P/FFO N/A
Growth
100 /100
Growing Book val. growth 32.08%
EPS growth N/A
Rev. growth N/A
Profitability
-
N/A Gross margin N/A
Net margin N/A
FCF margin N/A
Quality
40 /100
Average ROIC 642.09%
ROE 97,459.80%
Asset turnover 0.00x
Debt
77 /100
Low Current ratio 0.79x
Net debt/EBITDA 0.45x
Debt/Equity N/A
Stability
77 /100
Stable Beta 0.76x
EPS volatility 17.39%
Profitable years 0
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about NGENF
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Adam H. Rogers
Employees
11
Headquarters
Vancouver